Search

Your search keyword '"Letter to the Editor (Other)"' showing total 20 results
Start Over Descriptor "Letter to the Editor (Other)"
20 results on '"Letter to the Editor (Other)"'

1. Real-life experience of tocilizumab use in COVID-19 patients

Author

Madenidou, Anastasia-Vasiliki and Bukhari, Marwan

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, MEDLINE, Antibodies, Monoclonal, Humanized, chemistry.chemical_compound, Tocilizumab, Rheumatology, Internal medicine, Pandemic, medicine, Humans, Pharmacology (medical), Pandemics, business.industry, COVID-19, medicine.disease, Pneumonia, Treatment Outcome, chemistry, Letter to the Editor (Other), Monoclonal, Coronavirus Infections, business
Published
2020

2. To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery?

Author

Kulveer Mankia, Alice Wignall, Amar Rangan, Bernard H van Duren, Laura C. Coates, and Hemant Pandit

Subjects
medicine.medical_specialty, Rheumatology, business.industry, Letter to the Editor (Other), Orthopedic surgery, medicine, business, AcademicSubjects/MED00010, Surgery
Abstract

Management of biologic DMARDs in patients undergoing orthopaedic surgery is variable; flare avoidance is a priority.

Published
2021

3. Adapted treatment of ANCA associated vasculitis during the COVID-19 pandemic

Author

Ailish Nimmo and Saira Risdale

Subjects
2019-20 coronavirus outbreak, Rheumatology, Coronavirus disease 2019 (COVID-19), business.industry, Letter to the Editor (Other), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pandemic, MEDLINE, Medicine, ANCA-Associated Vasculitis, AcademicSubjects/MED00010, business, Virology
Published
2021

4. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Anja, Strangfeld, Martin, Schäfer, Milena, A Gianfrancesco, Saskia, Lawson-Tovey, Jean, W Liew, Lotta, Ljung, Elsa, F Mateus, Christophe, Richez, Maria, J Santos, Gabriela, Schmajuk, Carlo, A Scirè, Emily, Sirotich, Jeffrey, A Sparks, Paul, Sufka, Thierry, Thomas, Laura, Trupin, Zachary, S Wallace, Sarah, Al-Adely, Javier, Bachiller-Corral, Suleman, Bhana, Patrice, Cacoub, Loreto, Carmona, Ruth, Costello, Wendy, Costello, Laure, Gossec, Rebecca, Grainger, Eric, Hachulla, Rebecca, Hasseli, Jonathan, S Hausmann, Kimme, L Hyrich, Zara, Izadi, Lindsay, Jacobsohn, Patricia, Katz, Lianne, Kearsley-Fleet, Philip, C Robinson, Jinoos, Yazdany, Pedro, M Machado, COVID-19 Global Rheumatology Alliance, COVID-19 Global Rheumatology Alliance Consortium Collaborators: COVID-19 Global Rheumatology Alliance Consortium, Brahim, Dahou, Marcelo, Pinheiro, Francinne, M Ribeiro, Anne-Marie, Chassin-Trubert, Sebastián, Ibáñez, Lingli, Dong, Lui, Cajas, Hesham, Hamoud, Jérôme, Avouac, Véronique, Belin, Raphaël, Borie, Pascal, Chazerain, Xavier, Chevalier, Pascal, Claudepierre, Gaëlle, Clavel, Marie-Eve, Colette-Cedoz, Bernard, Combe, Elodie, Constant, Nathalie, Costedoat-Chalumeau, Marie, Desmurs, Valérie, Devauchelle-Pensec, Mathilde, Devaux, Robin, Dhote, Yannick, Dieudonné, Fanny, Domont, Pierre-Marie, Duret, Mikaël, Ebbo, Esther, Ebstein, Soumaya El Mahou, Bruno, Fautrel, Renaud, Felten, René-Marc, Flipo, Violaine, Foltz, Antoine, Froissart, Joris, Galland, Véronique, Gaud-Listrat, Sophie, Georgin-Lavialle, Aude, Giraud-Morelet, Jeanine, S Giraudet-Le Quitrec, Philippe, Goupille, Sophie, Govindaraju-Audouard, Franck, Grados, Séverine, Guillaume-Czitrom, Marion, Hermet, Ambre, Hittinger-Roux, Christophe, Hudry, Isabelle, Kone-Paut, Sylvain La Batide Alanore, Pierre, Lafforgue, Sophie, Lahalle, Isabelle, Lambrecht, Vincent, Langlois, Jean-Paul, Larbre, Emmanuel, Ledoult, Christophe, Leroux, Frédéric, Liote, Alexandre TJ Maria, Hubert, Marotte, Arsène, Mekinian, Isabelle, Melki, Laurent, Messer, Catherine, Michel, Gauthier, Morel, Jacques, Morel, Marie-Noelle, Paris-Havard, Edouard, Pertuiset, Thao, Pham, Myriam, Renard, Sabine, Revuz, Sébastien, Rivière, Clémentine, Rousselin, Christian, Roux, Diane, Rouzaud, Jérémie, Sellam, Raphaele, Seror, Amelie, Servettaz, Vincent, Sobanski, Christelle, Sordet, Lionnel, Spielmann, Nathalie, Tieulié, Alice, Tison, Sophie, Trijau, Alexandre, Virone, Ursula, Warzocha, Daniel, Wendling, Frederik, N Albach, Peer, Aries, Elvira, Decker, Urs, Hartmann, Joerg, Henes, Bimba, F Hoyer, Andreas, Krause, Klaus, Krüger, Hanns-Martin, Lorenz, Ulf, Müller-Ladner, Alexander, Pfeil, Anne, Regierer, Jutta, G Richter, Markus, Rihl, Tim, Schmeiser, Hendrik, Schulze-Koops, Christof, Specker, Reinhard, E Voll, Stephanie, Werner, Gabriela MG Melgar, Mahdi, Vojdanian, Andreoli, Laura, Elena, Bartoloni-Bocci, Maurizio, Benucci, Francesco, Campanaro, Marta, Caprioli, Davide, Carboni, Greta, Carrara, Edoardo, Cipolletta, Chiara, Crotti, Gloria, Dallagiacoma, Paola, Faggioli, Rosario, Foti, Franceschini, Franco, Fredi, Micaela, Giacomo, Guidelli, Florenzo, Iannone, Gianpiero, Landolfi, Caludia, Lomater, Ceciclia, Nalli, Simone, Parisi, Luca, Quartuccio, Bernd, Raffeiner, Rossella, Reggia, Marta, Riva, Nicoletta, Romeo, Cinzia, Rotondo, Ettore, Silvagni, Luigi, Sinigaglia, Ilaria, Tinazzi, Anna, Zanetti, Giovanni, Zanframundo, Fatemah, Abutiban, Deshiré, Alpízar-Rodríguez, Marina, R Gabayet, Fedra, Irazoque, Xochitl, Jimenez, Eduardo, Martín, Angel AC Ortiz, Tatiana, S Rodriguez-Reyna, Diana, C Rosete, Erick AZ Tehozol, David, Vega, Beatriz, Zaueta, Nasra, Al-Adhoubi, Babur, Salim, Enrique, Giraldo, Ariel, Salinas, Manuel, Ugarte-Gil, Diogo, Almeida, Miguel, Bernardes, Rita, C Machado, Maria, Rato, Samar, Al-Emadi, Richard, Conway, Rachael, Flood, Juan, J Alegre-Sancho, Montserrat, C Coro, Natalia de la Torre-Rubio, Jose, C Esteban, Maria del Martin, Jose, G Puerta, Johan, Back, Maryam, Dastmalchi, Brigitte, Dupré, Emma, Grenholm, Aase, Hensvold, Ann, Knight, Servet, Akar, Ozan, C Icacan, Laura, Chadwick, Kirsty, Devine, Sasha, Dunt, Lucia, Fusi, Caroline, M Jones, Elizabeth, Macphie, Elena, Nikiphorou, Diana, O'Kane, Sheila, O'Reilly, Samir, Patel, Rosaria, Salerno, Lucy, Thornton, Jenny, Tyler, Claire, Vandevelde, Elizabeth, Warner, Su-Ann, Yeoh, Sara, Baig, Hammad, Bajwa, Byung, Ban, Vernon, Berglund, Cassandra, Calabrese, Kristin, D'Silva, Angela, Dahle, Kathryn, Dao, Nicole, Daver, William, Davis, Walter, Dorman, Ezzati, Fatemeh, Theodore, Fields, Jody, Hargrove, Melissa, Harvey, Maren, Hilton, Tiffany, Hsu, Arundathi, Jayatilleke, David, Karp, Gilbert, Kepecs, Neil, Kramer, Concetta, Lamore, Nicholas, Lebedoff, Susan, Leonard, Sushama, Mody, Jennifer, Morgan, Emily, Pfeifer, Guillermo, Quiceno, Robert, Quinet, Elliot, Rosenstein, Eric, Ruderman, Evangeline, Scopelitis, Naomi, Serling-Boyd, Faizah, Siddique, Archibald, Skemp, Jeffrey, Sparks, Derrick, Todd, Karen, T Toribio, Rachel, Wallwork, Tameka, Webb-Detiege, Douglas, White, Jeffrey, Wilson, Melanie, Winter, Leanna, Wise, Anne, Wolff, Kristen, Young, Jerald, Zakem, Joann, Zell, and Kurt Zimmerman, Leibniz Forschungsinstitut für Molekulare Pharmakolgie = Leibniz Institute for Molecular Pharmacology [Berlin, Allemagne] (FMP), Leibniz Association, University of California, University of Manchester [Manchester], Boston University School of Medicine (BUSM), Boston University [Boston] (BU), Umeå University, EULAR standing committee of People with Arthritis/Rheumatism in Europe (PARE), CHU Bordeaux [Bordeaux], Club Rhumatismes et Inflammation, Faculdade de Medicina [Lisboa], Universidade de Lisboa (ULISBOA), Università degli Studi di Ferrara (UniFE), McMaster University [Hamilton, Ontario], Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), INSERM U1059, SAINBIOSE - Santé, Ingénierie, Biologie, Saint-Etienne (SAINBIOSE-ENSMSE), Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Ingénierie et Santé (CIS-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Universidad de Alcalá - University of Alcalá (UAH), Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Otago [Dunedin, Nouvelle-Zélande], Université de Lille, Technische Hochschule Mittelhessen - University of Applied Sciences [Giessen] (THM), University of Queensland [Brisbane], University College of London [London] (UCL), Repositório da Universidade de Lisboa, University of California (UC), Universidade de Lisboa = University of Lisbon (ULISBOA), Università degli Studi di Ferrara = University of Ferrara (UniFE), Santé Ingénierie Biologie Saint-Etienne (SAINBIOSE), Centre Ingénierie et Santé (CIS-ENSMSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Strangfeld, A, Schafer, M, Gianfrancesco, M, Lawson-Tovey, S, Liew, J, Ljung, L, Mateus, E, Richez, C, Santos, M, Schmajuk, G, Scire, C, Sirotich, E, Sparks, J, Sufka, P, Thomas, T, Trupin, L, Wallace, Z, Al-Adely, S, Bachiller-Corral, J, Bhana, S, Cacoub, P, Carmona, L, Costello, R, Costello, W, Gossec, L, Grainger, R, Hachulla, E, Hasseli, R, Hausmann, J, Hyrich, K, Izadi, Z, Jacobsohn, L, Katz, P, Kearsley-Fleet, L, Robinson, P, Yazdany, J, Machado, P, and HAL-SU, Gestionnaire

Subjects
Male, 0301 basic medicine, Aging, antirheumatic agents, Epidemiology, Azathioprine, Comorbidity, Disease, Global Health, Cardiovascular, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Odds Ratio, Immunology and Allergy, Registries, AcademicSubjects/MED00360, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, glucocorticoids, Middle Aged, health care, 3. Good health, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Letter to the Editor (Other), 6.1 Pharmaceuticals, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Public Health and Health Services, Female, epidemiology, Rituximab, medicine.drug, medicine.medical_specialty, Clinical Sciences, Immunology, autoimmune disease, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Autoimmune Disease, General Biochemistry, Genetics and Molecular Biology, Antibodies, Antineutrophil Cytoplasmic, 03 medical and health sciences, Rheumatology, Sulfasalazine, Rheumatic Diseases, Internal medicine, medicine, Humans, autoimmune diseases, outcome assessment, Aged, Rheumatology and Autoimmunity, 030203 arthritis & rheumatology, Reumatologi och inflammation, SARS-CoV-2, business.industry, Arthritis, Evaluation of treatments and therapeutic interventions, COVID-19, Odds ratio, medicine.disease, Arthritis & Rheumatology, Good Health and Well Being, 030104 developmental biology, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, COVID-19 Global Rheumatology Alliance, antirheumatic agent, glucocorticoid, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ., Objectives: To determine factors associated with COVID-19-related death in people with rheumatic diseases. Methods: Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category. Results: Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death. Conclusion: Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.

Published
2021

5. The impact of telerheumatology and COVID-19 on outcomes in a tertiary rheumatology service: a retrospective audit

Author

Laura Eades, Thilinie De Silva, S. Morton, Anna Antony, Sally Ayoub, Wendy Zhu, and Eric F Morand

Subjects
Male, 2019-20 coronavirus outbreak, Telemedicine, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MEDLINE, Audit, Tertiary Care Centers, Rheumatology, Internal medicine, Rheumatic Diseases, medicine, Humans, Pharmacology (medical), AcademicSubjects/MED00360, Retrospective Studies, Service (business), Medical Audit, business.industry, COVID-19, Retrospective cohort study, Middle Aged, medicine.disease, Letter to the Editor (Other), Female, Medical emergency, business
Published
2021

6. Survey of adult and paediatric rheumatology patients suggests information about COVID-19 vaccination will aid uptake

Author

Yosef Uzie, Saskya P Angevare, Carine Wouters, Richard P Beesley, Nico M Wulffraat, and Wendy Costello

Subjects
Adult, 2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Consumer Health Information, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Patient Acceptance of Health Care, Vaccination, Development of clear, concise, Rheumatology, Rheumatic Diseases, Letter to the Editor (Other), medicine, Humans, accessible information about COVID-19 vaccination for rheumatology patients will aid uptake, Pharmacology (medical), Self Report, business, Child, Paediatric rheumatology, AcademicSubjects/MED00360
Abstract

ispartof: RHEUMATOLOGY vol:60 issue:7 pages:3474-3475 ispartof: location:England status: published

Published
2021

7. Prevalence of anxiety and depression in patients with rheumatoid arthritis before and during the COVID-19 pandemic

Author

Hiromu Ito, Ryu Watanabe, Kazuko Nin, Akio Morinobu, Kosaku Murakami, Ayae Kinoshita, Motomu Hashimoto, Kazuaki Jindai, Takahiro Itaya, Mie Torii, Kyosuke Tanigawa, Koichi Murata, Masao Tanaka, Yuki Urai, and Shuichi Matsuda

Subjects
Adult, Male, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MEDLINE, Anxiety, Risk Assessment, Arthritis, Rheumatoid, Japan, Rheumatology, Internal medicine, Pandemic, medicine, Humans, In patient, Pharmacology (medical), Depression (differential diagnoses), AcademicSubjects/MED00360, Psychiatric Status Rating Scales, business.industry, Depression, COVID-19, medicine.disease, Mental Health, Rheumatoid arthritis, Letter to the Editor (Other), Antirheumatic Agents, Female, medicine.symptom, business, Needs Assessment
Published
2021
Full Text
View/download PDF

9. Clinical decision-making in remote rheumatology consultations: a service evaluation of new patient and inflammatory rheumatic disease follow-up appointments

Author

Ian C. Scott, Fay Manning, Jake Weddell, Shouma Dutta, Ahmed B Tarar, and Zoe Paskins

Subjects
Service (business), medicine.medical_specialty, business.industry, medicine.disease, R1, Rheumatology, Clinical decision making, RC927, Letter to the Editor (Other), Internal medicine, medicine, Medical emergency, Inflammatory rheumatic disease, AcademicSubjects/MED00010, business, RA
Abstract

Letter

Published
2021

10. Perceptions of opioid use and impact on quality of life in patients with musculoskeletal conditions within online health community forums

Author

Hassan Rana, William G Dixon, Meghna Jani, and Goran Nenadic

Subjects
medicine.medical_specialty, business.industry, media_common.quotation_subject, Opioid use, Quality of life (healthcare), Rheumatology, Letter to the Editor (Other), Perception, Family medicine, medicine, In patient, AcademicSubjects/MED00010, business, media_common
Published
2021

11. Use of subcutaneous immunoglobulin in inflammatory myositis

Author

Alan L Zhou, Catherine Ivory, and Nancy Maltez

Subjects
Pathology, medicine.medical_specialty, Rheumatology, business.industry, Letter to the Editor (Other), medicine, Subcutaneous immunoglobulin, AcademicSubjects/MED00010, medicine.disease, business, Myositis
Published
2021

12. Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients

Author

Alessandro Tomelleri, Elena Baldissera, Jacopo Ferrari, Giulio Cavalli, Giacomo De Luca, Adriana Cariddi, Barbara Suzzi, Lorenzo Dagna, Corrado Campochiaro, Cavalli, G., Cariddi, A., Ferrari, J., Suzzi, B., Tomelleri, A., Campochiaro, C., De Luca, G., Baldissera, E., and Dagna, L.

Subjects
2019-20 coronavirus outbreak, Fibromyalgia, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, MEDLINE, Betacoronavirus, COVID-19 Testing, Rheumatology, Rheumatic Diseases, Pandemic, medicine, Humans, Pharmacology (medical), Musculoskeletal Diseases, Glucocorticoids, Pandemics, AcademicSubjects/MED00360, Societies, Medical, business.industry, Clinical Laboratory Techniques, SARS-CoV-2, COVID-19, medicine.disease, Virology, Europe, Letter to the Editor (Other), Communicable Disease Control, Mixed effects, business, Coronavirus Infections, Immunosuppressive Agents
Abstract

The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a 'living document' and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available.

Published
2020
Full Text
View/download PDF

13. An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic

Author

Michael R. Ehrenstein, Su-Ann Yeoh, Rishi K Gupta, Pauline Buck, and Muhammad Shipa

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Injections, Subcutaneous, MEDLINE, Self Administration, Antibodies, Monoclonal, Humanized, Abatacept, Arthritis, Rheumatoid, chemistry.chemical_compound, Tocilizumab, Rheumatology, Internal medicine, Pandemic, medicine, Humans, Pharmacology (medical), Infusions, Intravenous, AcademicSubjects/MED00360, business.industry, Drug Substitution, SARS-CoV-2, COVID-19, Patient Preference, Treatment Outcome, chemistry, Letter to the Editor (Other), Antirheumatic Agents, Disease Progression, business, Decision Making, Shared, medicine.drug
Published
2020

14. Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?

Author

L Goulston, May Nwe Lwin, Brian Davidson, Christopher J Edwards, Dinny Wallis, Christopher Holroyd, and Hans de Graaf

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, Increased risk, Rheumatology, Letter to the Editor (Other), Internal medicine, Medicine, In patient, AcademicSubjects/MED00010, business
Published
2020
Full Text
View/download PDF

15. No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic

Author

Marco Maria Lizzio, Gerlando Natalello, Barbara Tolusso, Lucrezia Verardi, Stefano Alivernini, L. Mirone, L. Gigante, Enrico De Lorenzis, S. L. Bosello, Dario Bruno, Anna Laura Fedele, Luca Petricca, Elisa Gremese, Maria Rita Gigante, Pietro Rubortone, Angelo Zoli, Annamaria Paglionico, Lucia Lanzo, Giacomo Tanti, Clara Di Mario, Carlo Tur, Valentina Varriano, Fabrizio Melpignano, Giusy Peluso, S. Perniola, and A. Capacci

Subjects
2019-20 coronavirus outbreak, Settore MED/16 - REUMATOLOGIA, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Betacoronavirus, Rheumatology, Risk Factors, Rheumatic Diseases, Pandemic, Receptors, Medicine, Humans, Pharmacology (medical), Viral, Respiratory system, Pandemics, AcademicSubjects/MED00360, Biological Products, biology, business.industry, Interleukin-6, SARS-CoV-2, COVID-19, Pneumonia, biology.organism_classification, medicine.disease, Respiration Disorders, Virology, Receptors, Interleukin-6, Italy, Letter to the Editor (Other), SARS-CoV-2 pandemic, business, Coronavirus Infections, Immunosuppressive Agents
Published
2020
Full Text
View/download PDF

16. ‘Reducing anxiety and maintaining care’ during the COVID-19 pandemic

Author

Polly Livermore

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, Reducing anxiety, Rheumatology, Letter to the Editor (Other), Pandemic, Medicine, AcademicSubjects/MED00010, business, Intensive care medicine
Published
2020

17. COVID-19. an unexpected indication for anti-rheumatic therapies

Author

Manuela Di Franco, Bruno Lucchino, and Fabrizio Conti

Subjects
anti rheumatic therapies, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, MEDLINE, Antibodies, Monoclonal, Humanized, chloroquine, Betacoronavirus, Rheumatology, Pandemic, medicine, Humans, Pharmacology (medical), Pandemics, Clinical Trials as Topic, Sulfonamides, biology, business.industry, SARS-CoV-2, covid 19, Adalimumab, Drug Repositioning, COVID-19, biology.organism_classification, medicine.disease, Virology, COVID-19 Drug Treatment, Drug repositioning, Pneumonia, Purines, Antirheumatic Agents, Letter to the Editor (Other), Monoclonal, biology.protein, Azetidines, Pyrazoles, Antibody, business, Coronavirus Infections, Cytokine Release Syndrome, Hydroxychloroquine
Published
2020

18. Hydroxychloroquine and QT prolongation: reassuring data in approved indications

Author

Ravi Tejraj Mehta, Tarun Sharma, and Anil Pareek

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, Hydroxychloroquine, QT interval, Rheumatology, Letter to the Editor (Other), Internal medicine, Medicine, AcademicSubjects/MED00010, business, medicine.drug
Published
2020

20. Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine in vulnerable patients with giant cell arteritis

Author

Alessandro Biglia, Fausto Baldanti, Daniele Lilleri, Federica Bergami, Sara Monti, Carlomaurizio Montecucco, Emanuele Bozzalla Cassione, Irene Cassaniti, Alice Bartoletti, and Paolo Delvino

Subjects
Male, 2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Giant Cell Arteritis, Immunogenicity, Vaccine, Rheumatology, medicine, Humans, Pharmacology (medical), Pandemics, AcademicSubjects/MED00360, Aged, Immunosuppressive treatment, Messenger RNA, business.industry, Immunogenicity, COVID-19, medicine.disease, Virology, Giant cell arteritis, Letter to the Editor (Other), Female, business, Immunosuppressive Agents
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results